IRAK3

IRAK3, also known as IRAK-M, is a member of the interleukin-1 receptor-associated kinase (IRAK) family that primarily functions as a negative regulator of Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling^[1][2]. Mechanistically, IRAK3 inhibits the phosphorylation of IRAK1, thereby suppressing downstream activation of NF-κB and the NLRP3 inflammasome, reducing proinflammatory cytokine production^[2]. In metabolic disease models, IRAK3 expression in macrophages is induced by PPARγ agonists, promoting an M2 anti-inflammatory phenotype and attenuating insulin resistance and atherosclerosis^[1]. Pathway analyses further indicate that IRAK3 participates in NF-κB, MAPK, and cytokine-cytokine receptor signaling, integrating innate immune responses with metabolic regulation^[1]. Compared with other IRAK isoforms, IRAK3 lacks canonical kinase activity and acts primarily through scaffolding and inhibitory mechanisms, distinguishing it from IRAK1 and IRAK4 in both inflammatory and autoimmune contexts^[2]. Experimental evidence in autoimmune encephalomyelitis demonstrates that overexpression of IRAK3 limits neuroinflammation and pyroptosis in microglia, while knockout models exacerbate disease severity through enhanced IRAK1 phosphorylation^[2]. For research applications, modulation of IRAK3 using agonists or gene expression tools allows precise investigation of macrophage polarization, inflammatory signaling, and therapeutic strategies targeting TLR-mediated pathways^[1][2]. Overall, IRAK3 serves as a key checkpoint in innate immunity, linking receptor-mediated signaling to cellular homeostasis and disease modulation.